Study guide
14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
Key Takeaways Explain This Topic AI
Objective criteria for safe tracheal extubation include purposeful responsiveness, regular spontaneous breathing with tidal volume > 5 − 6 mL/kg >5-6\text{ mL/kg} > 5 − 6 mL/kg , intact protective airway reflexes, normothermia, and quantitative documentation of a Train-of-Four (TOF) ratio ≥ 0.90 \ge 0.90 ≥ 0.90 at the adductor pollicis muscle.
Post-extubation laryngospasm is an involuntary, sustained adduction of the vocal cords mediated by superior laryngeal nerve sensory afferents and recurrent laryngeal nerve motor efferents; immediate management comprises Larson's pressure point jaw thrust, 100 % 100\% 100% oxygen with continuous positive airway pressure (CPAP 20 − 30 cmH 2 O 20-30\text{ cmH}_2\text{O} 20 − 30 cmH 2 O ), deepening with propofol ( 0.5 − 1.0 mg/kg 0.5-1.0\text{ mg/kg} 0.5 − 1.0 mg/kg ), and low-dose suxamethonium ( 0.1 − 0.5 mg/kg 0.1-0.5\text{ mg/kg} 0.1 − 0.5 mg/kg ).
Negative Pressure Pulmonary Edema (NPPE) develops when vigorous spontaneous inspiratory efforts generate extreme negative intrathoracic pressures ( − 50 to − 100 cmH 2 O -50\text{ to } -100\text{ cmH}_2\text{O} − 50 to − 100 cmH 2 O ) against an obstructed upper airway, driving acute alveolar capillary hydrostatic fluid transudation; treatment requires positive airway pressure (CPAP/PEEP), whereas loop diuretics are not primarily indicated.
Postoperative Nausea and Vomiting (PONV) risk is quantified by the Apfel score (female sex, non-smoker, history of PONV/motion sickness, postoperative opioids; 10 % 10\% 10% , 21 % 21\% 21% , 39 % 39\% 39% , 61 % 61\% 61% , 79 % 79\% 79% risk for 0-4 factors); multimodal prophylaxis utilizes agents from distinct receptor classes ( 5 -HT 3 5\text{-HT}_3 5 -HT 3 , D 2 D_2 D 2 , corticosteroid, N K 1 NK_1 N K 1 ) alongside propofol-based total intravenous anaesthesia (TIVA).
Postoperative Delirium (POD) is an acute, fluctuating cognitive disturbance (hypoactive, hyperactive, or mixed) screenable with the CAM-ICU, triggered by anticholinergics and benzodiazepines; it is distinct from Postoperative Cognitive Dysfunction (POCD), which is a subtle, long-term neurocognitive decline documented by neuropsychological testing weeks to months postoperatively.
Last updated: October 2026
14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
The immediate post-anaesthesia period represents an acute transition phase where protective physiological reflexes are restored. Discontinuing anaesthetic agents does not instantly return the patient to baseline homeostasis. Clinicians must safely manage emergence, recognize life-threatening upper airway obstruction, treat postoperative nausea and vomiting, and assess readiness for discharge.
1. Emergence from General Anaesthesia and Objective Extubation Criteria
Emergence is an active neurobiological process characterized by the progressive restoration of brainstem vegetative reflexes, subcortical arousal networks, and frontoparietal cortical connectivity. [ SYSTEMATIC EXTUBATION CRITERIA ]
- |
- +--------------------------------+--------------------------------+
- | | |
- [ Ventilatory Mechanics ] [ Neuromuscular Recovery ] [ Neurological & Reflex Status ]
- Regular breathing pattern • Quantitative TOF ratio • Follows verbal commands
- Tidal volume > 5-6 mL/kg >= 0.90 at adductor • Sustained head lift > 5 s
- Respiratory rate 10-25/min pollicis muscle • Sustained strong hand grip
- SpO2 > 95% on FiO2 <= 0.4 • ZERO tactile fade is • Intact swallowing reflex
- Normocapnia (EtCO2 normal) INSUFFICIENT! • Active tongue protrusion
- Objective Extubation Criteria
Extubation must be deferred until the patient meets all of the following physiological criteria:
Ventilatory Mechanics:
Spontaneous, regular respiratory rhythm.
Tidal volume ( V T V_T V T ) > 5 − 6 mL/kg > 5-6\text{ mL/kg} > 5 − 6 mL/kg of ideal body weight.
Respiratory rate between 10 10 10 and 25 breaths/min 25\text{ breaths/min} 25 breaths/min .
Negative Inspiratory Force (NIF or P i , max P_{i,\max} P i , m a x ) more negative than − 25 to − 30 cmH 2 O -25\text{ to } -30\text{ cmH}_2\text{O} − 25 to − 30 cmH 2 O .
Adequate Oxygenation and Gas Exchange:
S p O 2 > 95 % Sp\text{O}_2 > 95\% Sp O 2 > 95% on F i O 2 ≤ 0.40 Fi\text{O}_2 \le 0.40 F i O 2 ≤ 0.40 (or patient's baseline room air saturation).
End-tidal CO 2 \text{CO}_2 CO 2 ( E t CO 2 Et\text{CO}_2 Et CO 2 ) < 45 mmHg < 45\text{ mmHg} < 45 mmHg ( < 6.0 kPa < 6.0\text{ kPa} < 6.0 kPa ) with stable arterial pH ( > 7.30 > 7.30 > 7.30 ).
Quantitative Neuromuscular Recovery:
Recovery of a Train-of-Four (TOF) ratio ≥ 0.90 \ge 0.90 ≥ 0.90 documented quantitatively using acceleromyography, electromyography, or kinemyography at the adductor pollicis muscle .
Critical Rule: Clinical tests (5-second head lift, hand grip) and subjective visual/tactile assessment using a peripheral nerve stimulator cannot detect residual neuromuscular blockade (clinicians cannot reliably detect tactile TOF fade when the true TOF ratio is between 0.40 0.40 0.40 and 0.80 0.80 0.80 ). Residual curarization (TOF ratio < 0.90) causes upper esophageal collapse, impairs pharyngeal coordination, increases the risk of aspiration and postoperative pulmonary complications, and blunts the hypoxic ventilatory response.
Airway Protective Reflexes and Consciousness:
Return of swallowing, active coughing, and phonation.
Purposeful response to verbal commands (opening eyes, sustained hand grip ≥ 5 seconds \ge 5\text{ seconds} ≥ 5 seconds , head lift off pillow ≥ 5 seconds \ge 5\text{ seconds} ≥ 5 seconds ).
Stable hemodynamics and core normothermia ( > 36.0 ∘ C > 36.0^\circ\text{C} > 36. 0 ∘ C ). Hypothermia impairs drug metabolism and paralyzes platelet function.
Awake versus Deep Extubation
Deep Extubation (Guedel Stage III, Plane 2): Tracheal tube is removed while the patient is deeply anesthetized under spontaneous breathing, before airway reflexes return. Advantages: Eliminates coughing, bucking, hemodynamic surges, and acute elevations in intraocular pressure (IOP), intracranial pressure (ICP), and surgical wound strain. Absolute Contraindications: Difficult airway, aspiration risk (full stomach, obesity, gastroesophageal reflux, hiatal hernia), prone or sitting surgery, impaired access to the airway, or morbid craniofacial distortion.
Awake Extubation: Standard of care for difficult airways, aspiration risk, and unstable patients; performed only after the patient demonstrates purposeful command following and airway defense.
- 2. Emergence Complications: Laryngospasm, NPPE, and Shivering
- Post-Extubation Laryngospasm
Laryngospasm is a sustained, involuntary reflex closure of the laryngeal musculature (primarily the lateral cricoarytenoid, transverse arytenoid, and thyroarytenoid adductor muscles) mediated by the internal branch of the superior laryngeal nerve (sensory afferent) and the recurrent laryngeal nerve (motor efferent) via the vagus nerve. It is triggered by blood, secretions, or surgical debris irritating the glottis during light anaesthesia (Guedel Stage II). [ STEPWISE LARYNGOSPASM ESCALATION ]
- Step 1: 100% O2 + Larson's Maneuver (Firm Bilateral Jaw Thrust at Styloid Notch)
- |
- v (Spasm Persists)
- Step 2: Tight Face Mask Seal + CPAP (20 - 30 cmH2O)
- |
- v (Hypoxia / Persistent Spasm)
- Step 3: Deepen Anaesthesia: IV Propofol (0.5 - 1.0 mg/kg)
- |
- v (Severe Spasm / Desaturation)
- Step 4: Neuromuscular Blockade: IV Suxamethonium (0.1 - 0.5 mg/kg) + Atropine
Step 1 — Oxygen and Larson's Maneuver: Discontinue stimulation. Apply 100 % O 2 100\%\text{ O}_2 100% O 2 . Perform Larson's maneuver (application of firm, sustained bilateral pressure directed anteriorly and medially into the "laryngospasm notch" behind the condyle of the mandible between the mastoid process and the ramus of the mandible; this intense periosteal stimulation breaks the adductor reflex arc while vigorously displacing the tongue and mandible anteriorly).
Step 2 — Continuous Positive Airway Pressure (CPAP): Apply a tight mask seal with 20 − 30 cmH 2 O 20-30\text{ cmH}_2\text{O} 20 − 30 cmH 2 O CPAP using the adjustable pressure-limiting (APL) valve. Continuous pressure splints the pharyngeal walls and pushes the false vocal cords laterally.
Step 3 — Pharmacological Deepening: Administer an intravenous bolus of propofol 0.5 − 1.0 mg/kg 0.5-1.0\text{ mg/kg} 0.5 − 1.0 mg/kg to suppress hyperactive brainstem reflexes.
Step 4 — Neuromuscular Blockade: If hypoxemia supervenes, administer low-dose suxamethonium 0.1 − 0.5 mg/kg 0.1-0.5\text{ mg/kg} 0.1 − 0.5 mg/kg IV (subparalytic dose that relaxes vocal cord adductors without requiring prolonged re-intubation). If IV access is lost, administer suxamethonium 2 − 4 mg/kg 2-4\text{ mg/kg} 2 − 4 mg/kg intramuscularly. In pediatric patients, pair with atropine 0.01 − 0.02 mg/kg 0.01-0.02\text{ mg/kg} 0.01 − 0.02 mg/kg to prevent suxamethonium-induced bradycardia.
Negative Pressure Pulmonary Edema (NPPE / Type I Post-Obstructive Pulmonary Edema)
NPPE occurs when a patient makes vigorous spontaneous inspiratory efforts against an acute upper airway obstruction (classic scenario: a young, muscular athletic male who develops post-extubation laryngospasm or bites the endotracheal tube upon emergence).
Pathophysiology: Massive inspiratory efforts generate extreme negative intrathoracic pressures down to − 50 to − 100 cmH 2 O -50\text{ to } -100\text{ cmH}_2\text{O} − 50 to − 100 cmH 2 O (normal quiet inspiration is − 3 to − 5 cmH 2 O -3\text{ to } -5\text{ cmH}_2\text{O} − 3 to − 5 cmH 2 O ). This massive negative pressure markedly increases venous return to the right ventricle, elevates pulmonary capillary transmural hydrostatic pressure, and physically disrupts the tight junctions of the alveolar-capillary membrane ("alveolar stress failure"). Rapid transudation of fluid and erythrocytes floods the alveoli.
Clinical Presentation: Acute respiratory distress, tachypnea, severe hypoxemia, bilateral diffuse alveolar infiltrates on chest radiograph, and copious pink, frothy pulmonary secretions appearing within minutes of relieving the obstruction.
Management: Re-establish a patent airway. Apply high-concentration oxygen with continuous positive airway pressure ( CPAP or PEEP 5 − 10 cmH 2 O 5-10\text{ cmH}_2\text{O} 5 − 10 cmH 2 O via face mask, or endotracheal re-intubation with mechanical ventilation). Clinical Pearl: NPPE is a non-cardiogenic, hydrostatic transudative edema in a typically euvolemic or hypovolemic patient; loop diuretics are not primarily indicated and can induce severe intravascular hypovolemia and hypotension. The disruption is temporary; with PEEP splinting, the edema clears spontaneously within 12 − 24 hours 12-24\text{ hours} 12 − 24 hours .
Post-Anaesthetic Shivering
Occurs in up to 50 % 50\% 50% of un-warmed recovery patients due to core-to-peripheral heat redistribution, inhibition of hypothalamic thermoregulation by volatile agents, and operative exposure.
Physiological Hazards: Shivering dramatically increases whole-body oxygen consumption ( V O 2 V\text{O}_2 V O 2 ) and carbon dioxide production ( V CO 2 V\text{CO}_2 V CO 2 ) by 200 − 400 % 200-400\% 200 − 400% , precipitating myocardial ischemia in patients with coronary disease, metabolic lactic acidosis, and dangerous elevations in intraocular and intracranial pressure.
Treatment: Active cutaneous forced-air warming blankets. Pharmacological interventions include meperidine (pethidine) 12.5 − 25 mg 12.5-25\text{ mg} 12.5 − 25 mg IV (the gold standard; acts on κ \kappa κ -opioid receptors to lower the shivering trigger threshold), tramadol 0.5 − 1.0 mg/kg 0.5-1.0\text{ mg/kg} 0.5 − 1.0 mg/kg , clonidine 1 − 2 μ g/kg 1-2\text{ }\mu\text{g/kg} 1 − 2 μ g/kg IV ( α 2 \alpha_2 α 2 -agonist), or magnesium sulfate.
3. Postoperative Nausea and Vomiting (PONV): Risk Scores and Receptor Pharmacology
PONV is one of the most common distressing complications following anaesthesia, leading to dehydration, electrolyte disturbances, suture dehiscence, esophageal rupture (Boerhaave syndrome), and delayed hospital discharge.
The Apfel Risk Score
The Apfel simplified scoring system evaluates 4 independent clinical predictors , each assigning 1 point:
- Female gender
- Non-smoker status
- History of PONV or motion sickness
- Postoperative opioid administration
- Apfel Predictors Present Stratified PONV Risk Category Baseline Incidence of PONV
- 0 Factors Very Low Risk ≈ 10 % \approx 10\% ≈ 10%
- 1 Factor Low Risk ≈ 21 % \approx 21\% ≈ 21%
- 2 Factors Moderate Risk ≈ 39 % \approx 39\% ≈ 39%
- 3 Factors High Risk ≈ 61 % \approx 61\% ≈ 61%
- 4 Factors Very High Risk ≈ 79 % \approx 79\% ≈ 79%
- Neuroanatomy and Emetic Receptor Systems
Emesis is coordinated by the vomiting center in the lateral reticular formation of the medulla oblongata (including the Nucleus Tractus Solitarius / NTS ), activated via four primary inputs:
Chemoreceptor Trigger Zone (CTZ): Located in the area postrema at the caudal floor of the 4th ventricle. Importantly, the area postrema lies outside the blood-brain barrier , allowing circulating toxins, emetogenic drugs (opioids, volatile anaesthetics), and metabolic byproducts direct access to CTZ receptors.
Vagal and Splanchnic Afferents: Gastrointestinal mucosal irritation and distension.
Vestibular System: Motion and middle ear surgery (via the 8th cranial nerve).
Higher Cortical Centers: Anticipatory nausea, anxiety, pain, and olfactory triggers. [ NEUROANATOMY OF EMESIS ]
- [ Vestibular System ] [ GI Vagal Afferents ]
- (H1 and M1 Receptors) (5-HT3 and NK1 Receptors)
- \ /
- \ /
- v v
- [ Chemoreceptor Trigger Zone ] ---> [ NUCLEUS TRACTUS SOLITARIUS ]
- (Area Postrema: D2, 5-HT3, NK1) (Vomiting Center: M1, H1, NK1)
- |
- v
- [ EMETIC REFLEX ]
- Multimodal Antiemetic Pharmacology
Combining antiemetics with distinct mechanisms of action yields additive or synergistic efficacy:
Drug Class Specific Agent & Dose Timing of Administration Receptor Mechanism & Clinical Pearls
5 -HT 3 5\text{-HT}_3 5 -HT 3 Receptor Antagonists Ondansetron ( 4 mg 4\text{ mg} 4 mg IV); Granisetron ( 1 mg 1\text{ mg} 1 mg IV) End of surgery (short t 1 / 2 ≈ 4 h t_{1/2} \approx 4\text{ h} t 1/2 ≈ 4 h ) Blocks serotonin 5 -HT 3 5\text{-HT}_3 5 -HT 3 receptors in the CTZ and GI vagal afferents. Administering at induction is less effective due to hepatic clearance during prolonged surgery. Potential QT interval prolongation.
Corticosteroids Dexamethasone ( 4 − 8 mg 4-8\text{ mg} 4 − 8 mg IV) Induction of anaesthesia Central inhibition of prostaglandin synthesis and release of endorphins; delayed onset of action ( 2 − 4 hours 2-4\text{ hours} 2 − 4 hours ), hence must be given at induction. Avoids wound infection or glycemic instability at single 4 − 8 mg 4-8\text{ mg} 4 − 8 mg doses.
Dopamine D 2 D_2 D 2 Antagonists Droperidol ( 0.625 − 1.25 mg 0.625-1.25\text{ mg} 0.625 − 1.25 mg IV) End of surgery Butyrophenone blocking D 2 D_2 D 2 receptors in the area postrema. Extremely effective at low doses. Black-box warning for QT prolongation applies to high psychiatric doses ( > 5 mg >5\text{ mg} > 5 mg ); microdoses are safe.
N K 1 NK_1 N K 1 Receptor Antagonists Aprepitant ( 40 mg 40\text{ mg} 40 mg oral pre-op); Fosaprepitant ( 150 mg 150\text{ mg} 150 mg IV) Preoperative (oral) or Induction (IV) Highly selective antagonist of substance P neurokinin-1 ( N K 1 NK_1 N K 1 ) receptors in the NTS and CTZ. Elimination half-life about 9 − 13 hours 9-13\text{ hours} 9 − 13 hours ; particularly effective at preventing vomiting, including later in the first 24 − 48 h 24-48\text{ h} 24 − 48 h .
Antihistamines & Anticholinergics Cyclizine ( 50 mg 50\text{ mg} 50 mg IV); Transdermal Scopolamine ( 1.5 mg 1.5\text{ mg} 1.5 mg ) Pre-op patch or post-induction IV Blocks H 1 H_1 H 1 and muscarinic M 1 M_1 M 1 receptors in the vestibular apparatus and solitary tract. Excellent for middle ear surgery and motion sickness history. Sedation, dry mouth, blurred vision.
Anaesthetic Modality Total Intravenous Anaesthesia (TIVA) Intraoperative infusion Propofol-based TIVA reduces baseline PONV risk by ≈ 30 % \approx 30\% ≈ 30% (equivalent to one prophylactic antiemetic); avoids emetogenic volatile halogenated agents and nitrous oxide ( N 2 O N_2O N 2 O ).
4. PACU Discharge Criteria: The Modified Aldrete Score
Discharge from the post-anaesthesia care unit to the ward is based on objective criteria rather than a fixed length of stay. The Modified Aldrete score (Aldrete, 1995) replaced skin colour in the original score with pulse oximetry. Each of five domains scores 0 to 2, giving a maximum of 10:
- Domain Score 2 Score 1 Score 0
- Activity Moves all four limbs on command Moves two limbs Moves no limbs
- Respiration Breathes deeply and coughs freely Dyspnoea or limited breathing Apnoeic
Circulation Blood pressure within ± 20 % \pm 20\% ± 20% of the pre-anaesthetic value Within ± 20 − 49 % \pm 20-49\% ± 20 − 49% Differs by ≥ 50 % \ge 50\% ≥ 50%
Consciousness Fully awake Rousable on calling Not responding
Oxygen saturation S p O 2 > 92 % SpO_2 > 92\% Sp O 2 > 92% breathing room air Needs supplemental oxygen to keep S p O 2 > 90 % SpO_2 > 90\% Sp O 2 > 90% S p O 2 < 90 % SpO_2 < 90\% Sp O 2 < 90% even with oxygen
A score of 9 or more is the usual threshold for discharge from phase I recovery.
The score does not assess pain, nausea, bleeding or the regional block level, so units add local criteria: controlled pain and PONV, a stable surgical site, adequate urine output where relevant, normothermia, and regression of neuraxial block before ward transfer.
For day-case patients going home, the Post-Anaesthetic Discharge Scoring System (PADSS) scores vital signs, activity, nausea and vomiting, pain, and surgical bleeding (each 0 to 2), again using a threshold of 9 or more. Mandatory voiding before discharge is no longer required for most low-risk procedures.
5. Postoperative Delirium and Perioperative Neurocognitive Disorders
The 2018 multispecialty nomenclature groups postoperative cognitive problems as perioperative neurocognitive disorders :
Postoperative delirium (POD): An acute, fluctuating disturbance of attention and awareness arising in hospital, usually within the first week after surgery (often in the first 72 hours).
Delayed neurocognitive recovery: Cognitive decline identified up to 30 days after surgery.
Postoperative neurocognitive disorder: Decline diagnosed between 30 days and 12 months; this replaces the research term postoperative cognitive dysfunction (POCD), which required formal neuropsychological testing.
Clinical Features and Screening
Delirium may be hyperactive (agitation, pulling at lines), hypoactive (quiet, drowsy, easily missed and associated with worse outcomes) or mixed . It is diagnosed with validated tools such as the Confusion Assessment Method (CAM), CAM-ICU in ventilated patients, the 4AT, or the Nursing Delirium Screening Scale (Nu-DESC). The ESAIC guideline on postoperative delirium (updated 2024) recommends screening at-risk patients from the recovery room and at least once per shift for several postoperative days.
Risk Factors and Prevention
Predisposing factors: Older age, pre-existing cognitive impairment or dementia, frailty, sensory impairment, alcohol misuse, and high comorbidity burden.
Precipitating factors: Emergency or major surgery, deep anaesthesia with burst suppression, benzodiazepines and anticholinergics (such as scopolamine), uncontrolled pain, hypoxaemia, sepsis, urinary retention, sleep deprivation, and electrolyte disturbance.
Prevention: Multicomponent non-drug bundles (reorientation, glasses and hearing aids, early mobilisation, sleep hygiene, hydration), processed EEG-guided depth of anaesthesia to avoid excessive depth, avoidance of benzodiazepines where possible, opioid-sparing analgesia, and treating causes promptly. Antipsychotics are not recommended for routine prevention, and low-dose haloperidol is reserved for distressing agitation once reversible causes have been addressed.
In the PACU, always exclude a physiological cause first: hypoxaemia, hypercapnia, hypoglycaemia, hypotension, a full bladder, pain, and residual neuromuscular blockade , which must be excluded with quantitative monitoring.